Market Newsdesk

VANCOUVER, BC, April 7, 2021 /PRNewswire/ — Gold Port Corporation (CSE: GPO) (PINK: GPOTF) (the “Company“) is providing a corporate update.

Groete Gold Copper Project Drill Program

Camp expansion at the Company owned Groete Gold Copper Project, located in Guyana, has been completed and the work site is now prepared for a phase one drill program. All planned drill holes have been located and confirmed to be accessible. No planned drill holes are within existing mining pits. Management are reviewing several drilling proposals, and interviewing potential key staff members.

The project was last explored in 2012, which included a drill program that allowed the calculation of an Inferred Mineral Resource of 1.57 million gold copper equivalent ounces within 74 million tonnes, at a grade of 0.66 grams per tonne gold copper equivalent. A cutoff grade of 0.25 gold copper ounce per tonne equivalent, a gold price of $ U.S 1,275 and copper price of $ 3.00 per pound was used in the calculation of the Inferred Mineral Resource.

The objective of the follow up drill program will be to potentially enhance the known resource from inferred to measured and indicated, and to also expand the deposit size. The first phase of the program is anticipated to include 2,500 meters totalling 12 holes.

Mr. William Feyerabend, a Consulting Geologist and Qualified Person under National Instrument 43-101, participated in the writing of, and has reviewed and approves of the technical disclosure contained in this press release.

Financial Update and Business Development

Management are pleased to report to the shareholders the current financial position of the Company. Corporate investments over the past year have returned significant gains resulting in the Company having a working capital balance of approximately Cdn $ 6,300,000. The proceeds will be utilized for the further development of the Company’s asset in Guyana.

To compliment and diversify the business of the Company, management are reviewing opportunities within the alternative energy space, and intend to make an acquisition in the near future.

The Canadian Securities Exchange has not reviewed, nor approved the contents of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities law and may not be offered or sold in the “United States“, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

ON BEHALF OF THE BOARD OF DIRECTORS

Adrian Hobkirk,
President, CEO and Director

T:     9546848040
E:     [email protected]

 

 

View original content:http://www.prnewswire.com/news-releases/drill-program-moving-ahead–corporate-update-301264035.html

SOURCE Gold Port Corporation

VANCOUVER, BC, April 7, 2021 /PRNewswire/ – Zacatecas Silver Corp. (“Zacatecas Silver” or the “Company”) (TSXV: ZAC) is pleased to announce it has completed first pass geological and structural mapping of the El Cristo Vein System. El Cristo is the northwestern strike extension of the Veta Grande vein. Since its discovery, the Veta Grande vein has reported historical production of over 200 Moz silver in the region.

Highlights:

• Multiple oxidized, silver-base metal mineralized veins defined over a strike length of at least 4 km significantly extending the previous reported strike length of 2.5 to 3.0 km.
• At least eight veins defined to date which are associated with a sigmoidal zone of extension that is at least 800 m wide.
• Only 8 angled diamond holes drilled by a previous operator — of which 6 were focused within a 400 m length.
• Significantly more historical shafts and surficial workings located than shown on existing maps — with many clustering along veins which have never been drill tested.
• Geological team has commenced an extensive soil sampling program to assist with location of veins beneath cover of thin soils.

The El Cristo vein system is in the central part of the Zacatecas Property. It is the northwest extension of the well-known Veta Grande vein and is defined by multiple vein outcrops, and extensive historical workings and shafts.  Significantly, the silver-base metal veins at El Cristo are associated with an extensive sigmoidal zone of dilation.

Dr Wilson, Chief Operating Officer and a Director of Zacatecas comments, “The presence of silver-base metal veins within a structurally-controlled zone of dilation — immediately to the northwest of the Veta Grande deposit — is highly significant. Dependent upon the orientation of the host structure, fault movement results in dilation, thereby providing fluid pathways for mineralizing fluids and the open space required for development of the higher-grade mineralized shoots“.

Large areas of El Cristo are blanketed by a thin soil which masks bedrock geology and vein outcrop, yet field work suggests that veins are likely to be more extensive than mapped.  Zacatecas Silver has commenced an aggressive soil sampling program to target vein extensions beneath cover.

Near surface historical workings and vertical shafts are more extensive than previously thought, as evidenced in high resolution satellite imagery and by surface mapping. Significantly, there are a large number of veins that have never been drill tested or channel sampled, yet have extensive surficial workings and historical shafts consistent with the presence of mineralization. Such veins are obvious drill ready targets.

Mapping has also defined a northern vein system that is more extensive than previously known, with the main vein extending over a strike length of at least 1 km. An extensive soil cover suggests further veins, or vein extensions, will be defined by a soil geochemical survey.

The cumulative strike length of all veins at El Cristo is at least 12 kilometres long. El Cristo an extremely prospective system with numerous high value targets at vein intersections, splays and flexures. Veins display multiphase and brecciated textures, indicative of multiple mineralizing events. Zacatecas Silver is planning an aggressive rock-chip and channel sampling program to better define the silver-base metal grade distribution of the outcropping veins, to ensure that the highest value targets are drill tested.

Qualified Person

The technical content of this news release has been reviewed, verified and approved by Dr. Chris Wilson,  B.Sc (Hons), PhD, FAusIMM (CP), FSEG. Chief Operating Officer and Director of Zacatecas Silver, a qualified person as defined by NI 43-101. 

About Zacatecas Silver Corp.

The Zacatecas Silver property is located in Zacatecas State, Mexico, within the highly prospective Fresnillo Silver Belt, which has produced over 6.2 billion ounces of silver. The company holds 7826 ha (19,338 acres) of ground that is highly prospective for low and intermediate sulphidation silver-base metal mineralization and potentially low sulphidation gold-dominant mineralization.

The property is 25 km south-east of MAG Silver Corp.’s Juanicipio Mine and Fresnillo PLC’s Fresnillo Mine. The property shares common boundaries with Pan American Silver Corp. claims and El Orito which is owned by Endeavour Silver. There are four main high-grade silver target areas within the Zacatecas concessions: the Panuco Deposit, Muleros, El Cristo and San Manuel-San Gill.  The Property also includes El Oro, El Orito, La Cantera, Monserrat, El Peñón, San Judas and San Juan silver-base metal vein targets. These targets are relatively unexplored and will be the focus of rapid reconnaissance review

On behalf of the Company
Bryan Slusarchuk
Chief Executive Officer and Director

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Zacatecas Silver cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by many material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to Zacatecas Silver’s limited operating history, its proposed exploration and development activities on is Zacatecas Properties and the need to comply with environmental and governmental regulations.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Zacatecas Silver does not undertake to publicly update or revise forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/zacatecas-silver-completes-geological-and-structural-mapping-at-the-el-cristo-prospect-and-confirms-multiple-silver-base-metal-mineralized-veins-over-a-strike-length-of-at-least-4-km-301263964.html

SOURCE Zacatecas Silver Corp.

EMMAC brings vertically integrated operations in Europe with a presence in key medical cannabis markets, including the UK, Germany, Italy, Spain, and Portugal

Strategic investor to fund cash portion of acquisition and Curaleaf’s growth initiatives in Europe

WAKEFIELD, Mass., April 7, 2021 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis has successfully completed the previously announced acquisition of EMMAC Life Sciences Limited (“EMMAC”), the largest vertically integrated independent cannabis company in Europe, for base consideration of approximately US$50 million in cash and 17.5 million shares of Curaleaf, with additional consideration to be paid based upon the successful achievement of performance milestones. Curaleaf has simultaneously established Curaleaf International Holdings Limited (“Curaleaf International”) in Guernsey to hold the EMMAC investment and further its European expansion. 

To accelerate the expansion of Curaleaf International, Curaleaf has secured an investment of US$130 million from a single strategic institutional investor in exchange for 31.5% equity stake in Curaleaf International, implying a $413 million Post Money valuation, with US$80 million in cash available to spend. The subscription will fund the entire cash portion of the EMMAC acquisition consideration of US$50 million with the remaining US$80 million to be used to fund Curaleaf International’s current capital expenditures plan through 2022, as well as its pipeline of potential acquisitions. This infusion of outside capital into Curaleaf International significantly accelerates Curaleaf’s expansion plans in Europe by fully funding Curaleaf’s cash outlay for the EMMAC acquisition and providing the capital required to support Curaleaf International’s near-term European rollout. With its foreseeable expansion budget fully funded, Curaleaf’s new international business can focus on executing its further European expansion.

Curaleaf and the strategic investor have entered into a shareholders’ agreement regarding the governance of Curaleaf International pursuant to which Curaleaf will have control over operational issues as well as raising capital and the ability to exit the business. In addition, the strategic investor’s stake is subject to put/call rights which permits either party to cause the stake to be bought out by Curaleaf for Curaleaf equity starting in 2025.

Boris Jordan, Executive Chairman of Curaleaf, stated, “The successful completion of our acquisition of EMMAC, and the formation of our new Curaleaf International business, marks a transformational launching point for our entrance into the European cannabis market. Building on our market leading position in the U.S., this transaction establishes Curaleaf as the global, pure play, cannabis market leader by revenue and geographic reach. With our single strategic institutional investor, we have set a strong foundation for Curaleaf International’s future growth trajectory. On behalf of the Curaleaf Board of Directors and management team, we are thrilled to welcome Antonio Costanzo, co-founder and CEO of EMMAC, as the CEO of Curaleaf International, and the entire EMMAC team to Curaleaf.”

The new Curaleaf International platform includes cultivation, EU GMP-certified processing, distribution, and R&D operations across several key European medical cannabis markets, including the United Kingdom, Germany, Italy, Spain and Portugal. Terra Verde, Curaleaf International’s European market cultivation facility in Portugal, is one of the oldest licensed cannabis growing facilities in Europe with approximately 2 hectares of cultivation area and is an industry leader on the cannabis production cost efficiency front. The Portugal based cultivation facility provides Curaleaf International with the potential to serve customers across key European medical cannabis markets as well as supporting exports to countries such as Israel, among others. Curaleaf International plans to significantly increase its cultivation capacity in 2021, and to exceed 10 tons per year by 2022, in order to accommodate future growth related to the expansion of access to cannabis across the major European medical and adult-use, as well as export markets. Curaleaf International also has an operational presence and partnerships in European Union countries that are enacting new medical cannabis access programs. Curaleaf International will also serve as the platform for other possible acquisitions in Europe and adjacent areas, and for its participation in pilot adult use programs.

Joseph Bayern, CEO of Curaleaf, commented, “As the consumer and political liberalization trends around cannabis that are sweeping the U.S. are increasingly taking hold across Europe, our expansion into the international cannabis market presents tremendous new long-term growth opportunities for Curaleaf. With the European population of nearly 748 million¹, the potential European addressable market is more than twice the size of the U.S. addressable market². With the ability to operate our new European business across country borders, with one or two cultivation sites and one manufacturing center to serve the entire region in most cases, combined with our ability to leverage the strength of our consumer packaged goods strategies and innovations from our U.S. operations, we see enormously positive implications for our ability to quickly and efficiently scale the business across Europe.”

Following the successful completion of the transaction, Mr. Antonio Costanzo has been appointed as the new Chief Executive Officer of Curaleaf International, with the former EMMAC management team continuing to lead Curaleaf’s new European presence as well as driving local European strategy and day-to-day operations.

Antonio Costanzo, CEO of Curaleaf International, commented, “This is an important day for the European cannabis market as EMMAC transitions to Curaleaf International. I look forward to working closely with the Curaleaf team to shape the future of cannabis for our patients and customers around the world. We will retain our science-led approach to continue to deliver best in class cannabis products for Europe’s growing medical cannabis market, and will work closely to leverage the consumer packaged goods experience and innovation from the U.S. to capitalize on the emerging adult-use market as legislation allows. We are now very well positioned to realize our aggressive growth ambitions.”

About Curaleaf Holdings

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 23 states with 103 dispensaries, 22 cultivation sites and over 30 processing sites, and employs over 4,600 team members. Curaleaf International, is the largest vertically integrated independent cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements

This news release contains forward–looking statements and forward–looking information within the meaning of applicable securities laws which include, but are not limited to, the transaction described above, the investment by an outside financial investor group described above, the anticipated benefits of the transaction and the outside investment described above, the anticipated use of the funds obtained from the outside financial investor group, the expected market size for cannabis in Europe, the expected penetration of Curaleaf’s products in Europe, the expected expansion of Curaleaf’s international footprint, Curaleaf International’s acquisition pipeline, the emergence of adult-use markets in Europe. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the acquisition of EMMAC Life Sciences Limited and the outside investment by a financial investor group, each as described above. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release. These assumptions include, but are not limited to, successfully integrating the business of EMMAC and to realize the anticipated benefits to Curaleaf of the transaction described above, the ability of Curaleaf to increase the cultivation activity of Terra Verde, Curaleaf’s ability to serve customers in various European markets, the assumption that the cannabis consumption habits in European markets will replicate the cannabis consumption habits in the US, the assumption that demand for cannabis products in Europe will continue to grow, the assumption that Curaleaf, EMMAC and its subsidiaries will obtain, maintain and renew the licenses required for them to operate their business in the various European jurisdictions in which EMMAC and its subsidiaries operate, the assumption that an adult-use market will materialize and grow in Europe, and the Company’s ability to realize its European growth prospects. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and other factors may include, but are not limited to: general business, economic, political and social uncertainties; general capital market conditions and market prices for securities; the risk that Curaleaf may not be able to successfully integrate the business of EMMAC and their respective corporate cultures; the risk that the benefits of the transaction anticipated by Curaleaf may not materialize; competition and changes in legislation affecting Curaleaf or EMMAC; the inability of Curaleaf, EMMAC and its subsidiaries obtain, maintain and renew the licenses required for them to operate their business in the various European jurisdictions in which EMMAC and its subsidiaries operate; potential importation or exportation restrictions prohibiting EMMAC or its subsidiaries to export its products in other jurisdictions; the risk that the benefits of the outside investment described above anticipated by Curaleaf may not materialize; and that an adult-use European market may not develop on the scale anticipated by Curaleaf, or at all. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed September 25, 2020, which is available under the Company’s SEDAR profile at www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this news release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Investor Contact:
Curaleaf Holdings, Inc.
Carlos Madrazo, SVP
[email protected]

Media Contact:
Curaleaf Holdings, Inc.
Tracy Brady, VP Corporate Communications
[email protected]

¹ European market population based on United Nations 2020 estimate for European continent.
² Total European addressable market based on usage rates and spend estimates from U.S. Data from Cowen October 2020 research report.

View original content:http://www.prnewswire.com/news-releases/curaleaf-completes-acquisition-of-emmac-and-secures-us130-million-investment-from-a-single-strategic-institutional-investor-301264049.html

SOURCE Curaleaf Holdings, Inc.

NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22. A total of 33 abstracts, including one podium presentation during the Clinical Trials Plenary Session and three oral presentations, will be shared from a broad range of studies across the spectrum of migraine, advanced Parkinson’s disease and spasticity.

“Our strong presence at AAN reflects our expanded portfolio of approved and investigational treatments designed to address a wide range of complicated, often debilitating neurological disorders,” said Michael Gold, M.D., vice president, neuroscience development, AbbVie. “We look forward to sharing our progress in a number of areas, including pivotal Phase 3 data in migraine, with the goal of making a remarkable impact on patients’ lives.”

Researchers will present data from several studies on migraine, including new findings on atogepant, AbbVie’s investigational preventive treatment of migraine in adults who meet criteria for episodic migraine as well as results evaluating the efficacy and safety of BOTOX^® (onabotulinumtoxinA) and UBRELVY^® (ubrogepant).

In addition, investigators will present the study design of the Phase 3 study assessing the efficacy and safety of the investigational treatment ABBV-951 (foslevodopa/foscarbidopa), a levodopa/carbidopa prodrug administered as a 24-hour continuous, subcutaneous infusion in people with advanced Parkinson’s disease.

Key AbbVie abstracts and presentation details for the 2021 AAN Annual Meeting program are outlined below. Posters will be available during and for 30 days following the meeting.

A full list of all 33 AbbVie abstracts accepted for presentation at the 2021 AAN Annual Meeting can be found here.

About Atogepant
Atogepant is an investigational orally administered, CGRP receptor antagonist (gepant) specifically developed for the preventive treatment of migraine. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks and selective CGRP receptor antagonists confer clinical benefit in migraine.

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for atogepant. AbbVie anticipates a regulatory decision in late Q3 2021.

About ABBV-951

ABBV-951 (foslevodopa/foscarbidopa) is a continuous subcutaneous infusion being investigated for the treatment of advanced Parkinson’s disease.

About BOTOX

^®

BOTOX^® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. Today, BOTOX^® is FDA-approved for 12 therapeutic indications, including Chronic Migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults, cervical dystonia, adult and pediatric spasticity, severe underarm sweating (axillary hyperhidrosis), and pediatric detrusor overactivity associated with a neurologic condition.

BOTOX^® (onabotulinumtoxinA) Important Information

Indications

BOTOX^® is a prescription medicine that is injected into muscles and used:

• To treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken
• To treat leakage of urine (incontinence) in adults 18 years and older with overactive bladder caused by a neurologic disease who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication
• To treat overactive bladder due to a neurologic disease in children 5 years of age and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken
• To prevent headaches in adults with chronic migraine who have 15 or more days each month with headache lasting 4 or more hours each day in people 18 years or older
• To treat increased muscle stiffness in people 2 years of age and older with spasticity
• To treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older
• To treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years of age and older

BOTOX^® is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.

It is not known whether BOTOX^® is safe and effective to prevent headaches in patients with migraine who have 14 or fewer headache days each month (episodic migraine).

BOTOX^® has not been shown to help people perform task-specific functions with their upper limbs or increase movement in joints that are permanently fixed in position by stiff muscles. 

It is not known whether BOTOX^® is safe and effective for severe sweating anywhere other than your armpits. 

IMPORTANT SAFETY INFORMATION

BOTOX
^® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX^®:

• Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months
• Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing

There has not been a confirmed serious case of spread of toxin effect away from the injection site when BOTOX^® has been used at the recommended dose to treat chronic migraine, severe underarm sweating, blepharospasm, or strabismus.

BOTOX^® may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX^®. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Do not receive BOTOX
^®
if you: are allergic to any of the ingredients in BOTOX^® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc^® (rimabotulinumtoxinB), Dysport^® (abobotulinumtoxinA), or Xeomin^® (incobotulinumtoxinA); have a skin infection at the planned injection site.

Do not receive BOTOX
^®
for the treatment of urinary incontinence if you: have a urinary tract infection (UTI) or cannot empty your bladder on your own and are not routinely catheterizing. Due to the risk of urinary retention (not being able to empty the bladder), only patients who are willing and able to initiate catheterization post treatment, if required, should be considered for treatment.

Patients treated for overactive bladder:

In clinical trials, 36 of the 552 patients had to self-catheterize for urinary retention following treatment with BOTOX^® compared to 2 of the 542 treated with placebo. The median duration of post-injection catheterization for these patients treated with BOTOX^® 100 Units (n = 36) was 63 days (minimum 1 day to maximum 214 days) as compared to a median duration of 11 days (minimum 3 days to maximum 18 days) for patients receiving placebo (n = 2). Patients with diabetes mellitus treated with BOTOX^® were more likely to develop urinary retention than nondiabetics. 

Adult Patients treated for overactive bladder due to neurologic disease:

In clinical trials, 30.6% of patients (33/108) who were not using clean intermittent catheterization (CIC) prior to injection, required catheterization for urinary retention following treatment with BOTOX^® 200 Units as compared to 6.7% of patients (7/104) treated with placebo. The median duration of post-injection catheterization for these patients treated with BOTOX^® 200 Units (n = 33) was 289 days (minimum 1 day to maximum 530 days) as compared to a median duration of 358 days (minimum 2 days to maximum 379 days) for patients receiving placebo (n = 7). Among patients not using CIC at baseline, those with MS were more likely to require CIC post injection than those with SCI.

The dose of BOTOX
^®
is not the same as, or comparable to, another botulinum toxin product.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, dizziness, or feeling faint. Get medical help right away if you experience symptoms; further injection of BOTOX^® should be discontinued.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig’s disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing from typical doses of BOTOX^®.

Tell your doctor if you have any breathing-related problems. Your doctor may monitor you for breathing problems during treatment with BOTOX^® for spasticity or for detrusor overactivity associated with a neurologic condition. The risk of developing lung disease in patients with reduced lung function is increased in patients receiving BOTOX^®.

Cornea problems have been reported. Cornea (surface of the eye) problems have been reported in some people receiving BOTOX^® for their blepharospasm, especially in people with certain nerve disorders. BOTOX^® may cause the eyelids to blink less, which could lead to the surface of the eye being exposed to air more than is usual. Tell your doctor if you experience any problems with your eyes while receiving BOTOX^®. Your doctor may treat your eyes with drops, ointments, contact lenses, or with an eye patch.

Bleeding behind the eye has been reported. Bleeding behind the eyeball has been reported in some people receiving BOTOX^® for their strabismus. Tell your doctor if you notice any new visual problems while receiving BOTOX^®.

Bronchitis and upper respiratory tract infections (common colds) have been reported. Bronchitis was reported more frequently in adults receiving BOTOX^® for upper limb spasticity. Upper respiratory infections were also reported more frequently in adults with prior breathing-related problems with spasticity. In pediatric patients treated with BOTOX^® for upper limb spasticity, upper respiratory tract infections were reported more frequently. In pediatric patients treated with BOTOX^® for lower limb spasticity, upper respiratory tract infections were not reported more frequently than placebo.

A
u
t
onomic dysreflexia in patients treated for overactive bladder due to neurologic disease. Autonomic dysreflexia associated with intradetrusor injections of BOTOX^® could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy. In clinical trials, the incidence of autonomic dysreflexia was greater in adult patients treated with BOTOX^® 200 Units compared with placebo (1.5% versus 0.4%, respectively).

Tell your doctor about all your medical conditions, including if you: have or have had bleeding problems; have plans to have surgery; had surgery on your face; weakness of forehead muscles; trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; have symptoms of a urinary tract infection (UTI) and are being treated for urinary incontinence (symptoms of a urinary tract infection may include pain or burning with urination, frequent urination, or fever); have problems emptying your bladder on your own and are being treated for urinary incontinence; are pregnant or plan to become pregnant (it is not known if BOTOX^® can harm your unborn baby); are breastfeeding or plan to (it is not known if BOTOX^® passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX^® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX^®in the past.

Tell your doctor if you received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc^®, Dysport^®, or Xeomin^®in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

Other side effects of BOTOX
^®
include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, dry eyes; drooping eyebrows; and upper respiratory tract infection. In adults being treated for urinary incontinence, other side effects include urinary tract infection and painful urination. In children being treated for urinary incontinence, other side effects include urinary tract infection and bacteria in the urine. If you have difficulty fully emptying your bladder on your own after receiving BOTOX^®, you may need to use disposable self-catheters to empty your bladder up to a few times each day until your bladder is able to start emptying again.

For more information refer to the Medication Guide or talk with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see BOTOX
^®
full

Product Information

, including Boxed Warning and Medication Guide.

About UBRELVY^® (ubrogepant)

UBRELVY^® (ubrogepant) is an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine with or without aura in adults that is an option for a wide range of patients who experience migraine attacks. UBRELVY^® is the first pill of its kind to directly block CGRP, a protein released during a migraine attack, from binding to its receptors.

IMPORTANT SAFETY INFORMATION
Who should not take UBRELVY^® (ubrogepant)?

Do not take UBRELVY^® if you are taking medicines known as strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, itraconazole.
What should I tell my healthcare provider before taking UBRELVY^®?
Tell your healthcare provider about all your medical conditions, including if you:

• Have liver problems
• Have kidney problems
• Are pregnant or plan to become pregnant
• Are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider can tell you if it is safe to take UBRELVY^® with other medicines.

What are the most common side effects of UBRELVY^®?

The most common side effects are nausea (4%) and sleepiness (3%). These are not all of the possible side effects of UBRELVY^®.

What is UBRELVY^® (ubrogepant)?

UBRELVY^® is a prescription medicine used for the acute treatment of migraine attacks with or without aura in adults. UBRELVY^® is not used to prevent migraine headaches.
Please see full Prescribing Information.

About DUOPA

DUOPA (carbidopa and levodopa) enteral suspension is a prescription medicine used for treatment of advanced Parkinson’s disease. DUOPA contains two medicines: carbidopa and levodopa.

Important Safety Information

What is the most important safety information I should know about DUOPA?

• Stomach and intestine (gastrointestinal) problems and problems from the procedure you will need to have to receive DUOPA (gastrointestinal procedure-related problems) may occur. Some of these problems may require surgery and may lead to death.
• Serious side effects may include: a blockage of your stomach or intestines (bezoar); stopping movement through intestines (ileus); drainage, redness, swelling, pain, feeling of warmth around the small hole in your stomach wall (stoma); bleeding from stomach ulcers or your intestines; inflammation of your pancreas (pancreatitis); infection in your lungs (pneumonia); air or gas in your abdominal cavity; skin infection around the intestinal tube, pocket of infection (abscess), or infection in your blood (sepsis) or abdominal cavity may occur after surgery; stomach pain, nausea, or vomiting.
• Tell your healthcare provider right away if you have any of the following symptoms of stomach and intestine problems and gastrointestinal procedure-related problems: stomach (abdominal) pain; constipation that does not go away; nausea or vomiting; fever; blood in your stool; or a dark tarry stool.

Your healthcare provider will talk to you about the stoma procedure. Before the stoma procedure, tell your healthcare provider if you ever had a surgery or problems with your stomach.

Talk to your healthcare provider about what you need to do to care for your stoma. After the procedure, you and your healthcare provider will need to regularly check the stoma for any signs of infection.

Do not take DUOPA if you currently take or have recently taken (within 2 weeks) a medication for depression called a non-selective monoamine oxidase (MAO) inhibitor. Ask your healthcare provider or pharmacist if you are not sure if you take an MAO inhibitor.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using DUOPA with certain other medicines, including medications for high blood pressure, MAO inhibitors, antipsychotics, metoclopramide, isoniazid, and iron or vitamin supplements, may cause serious side effects. High-protein foods may affect how DUOPA works. Tell your healthcare provider if you change your diet.

DUOPA may cause serious side effects. Talk to your doctor before starting DUOPA and while on DUOPA if you have had or have any of these:

• Falling asleep during normal daily activities without warning. DUOPA may cause you to fall asleep while you are doing daily activities such as driving, which may result in an accident. This can happen as late as one year after starting DUOPA. Do not drive or operate machinery until you know how DUOPA affects you. Tell your healthcare provider if you take medicines that can make you sleepy, such as sleep medicines, antidepressants, or antipsychotics.
• Low blood pressure when you stand or sit up quickly. After you have been sitting or lying down, stand up slowly to help reduce dizziness, nausea, sweating, or fainting until you know how DUOPA affects you.
• Seeing, hearing, or feeling things that are not real (hallucinations).
• Unusual urges. Some people taking medicines for Parkinson’s disease, including DUOPA, have reported urges such as excessive gambling, compulsive eating, compulsive shopping, and increased sex drive.
• Depression and suicide. DUOPA can cause or worsen depression. Pay close attention to changes in your mood, behavior, thoughts, or feelings. Call your healthcare provider right away if you feel depressed or have thoughts of suicide.
• Uncontrolled sudden movements (dyskinesia). If you have new dyskinesia or your dyskinesia gets worse, tell your healthcare provider. This may be a sign that your dose of DUOPA or other Parkinson’s medicines may need to be adjusted.
• Progressive weakness
  or numbness or loss of sensation in the fingers or feet (neuropathy).
• Heart attack or other heart problems. Tell your healthcare provider if you have experienced increased blood pressure, a fast or irregular heartbeat, or chest pain.
• Abnormal blood tests. DUOPA may cause changes in certain blood tests, especially certain hormone and kidney function blood tests.
• Worsening of the increased pressure in your eyes (glaucoma). The pressure in your eyes should be checked after starting DUOPA.

Do not stop using DUOPA or change your dose unless you are told to do so by your healthcare provider. Tell your healthcare provider if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.

The most common side effects of DUOPA include: complications of tubing placement procedure, swelling of legs and feet, nausea, high blood pressure (hypertension), depression, and mouth and throat pain.

Please see the

full Prescribing Information

 including Medication Guide for additional information about DUOPA.

About AbbVie Leadership in Migraine

AbbVie, a leader in the migraine space, markets BOTOX^® (onabotulinumtoxinA), the first FDA-approved, preventive treatment for adults with Chronic Migraine and UBRELVY^® (ubrogepant), the first FDA-approved oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), which is indicated for the acute treatment of migraine with or without aura in adults.

About AbbVie in Neuroscience
At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie’s Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders, including Alzheimer’s disease, bipolar I disorder, major depressive disorder, migraine, Parkinson’s disease, spinal cord injuries, post-stroke spasticity, schizophrenia, stroke and others.

We have a strong investment in neuroscience research, with our Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience Discovery site in Ludwigshafen, Germany, where our research and resilience in these challenging therapeutic areas is yielding a deeper understanding of the pathophysiology of neurological and psychiatric disorders, and identifying targets for potential disease-modifying therapeutics aimed at making a difference in people’s lives.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements


Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie’s acquisition of Allergan plc (“Allergan”), failure to promptly and effectively integrate Allergan’s businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

View original content:http://www.prnewswire.com/news-releases/abbvie-to-present-data-across-its-robust-neuroscience-portfolio-at-the-2021-american-academy-of-neurology-aan-annual-meeting-301263600.html

SOURCE AbbVie

WATERLOO, ON, April 7, 2021 /PRNewswire/ — BlackBerry Limited (NYSE: BB; TSX: BB) today announced that Volvo Group, one of the world’s leading manufacturers of heavy-duty trucks, buses and construction equipment, has selected BlackBerry QNX as the foundational software for its main domain controller ECUs in more than 300,000 heavy vehicles Volvo Group manufactures every year.

To realize its vision for the electronic architecture of future generations of vehicles, Volvo Group wanted to take a new approach to software. It wanted to find a single supplier for the operating system (OS) and hypervisor to meet the needs of the ‘whole truck’, capable of supporting safety certification to the highest levels.

Following an in-depth proof of concept, Volvo Group decided to build its ‘Volvo Dynamic Software Platform’ (VDSP) on the QNX® OS for Safety and the QNX® Hypervisor for Safety, both certified to ISO 26262:2018 ASIL D. The engagement includes a new flexible use of the QNX OS and Hypervisor for the whole vehicle, which gives developers and architects the freedom to design the best possible system as the company looks at the requirements of the next 15 years, including the future support of autonomous driving and electrification.

Pre-integration with several Adaptive AUTOSAR suppliers was a primary reason Volvo Group chose BlackBerry QNX. Plus, with high levels of Portable Operating System Interface (POSIX) compliance, engineers building on BlackBerry QNX can write software for a wide range of applications with a common API.

“BlackBerry QNX is a true partner and has provided us with the foundation we need to produce the safe and secure vehicles of tomorrow,” said Mark Mohr, Senior Vice President Vehicle Technology at Volvo Group. “BlackBerry is well aligned with the automotive challenges within electrification, automation and connectivity and the technical solutions needed in these domains.”

BlackBerry QNX is trusted by more than 68% of the Electric Vehicle market by volume, 23 of the top 25 EV manufacturers and is running in more than 175 million vehicles globally.  Foundational software from BlackBerry QNX has been pre-certified to many industry safety standards including ISO 26262, IEC 61508 and IEC 62304, and has also been recognized by the independent auditors at TÜV Rheinland as the world’s first ASIL D safety-certified commercial hypervisor.

“We are delighted to extend our partnership with the Volvo Group and help bring to market their world-class fleet of commercial vehicles,” said John Wall, Senior Vice President and Co-Head of BlackBerry Technology Solutions. “OEMs are constantly looking to deploy the right software foundation for the safe and secure architecture of the whole truck, and with BlackBerry QNX we are able to deliver the components and functionality needed to make this possible.”

For more information how BlackBerry QNX can help with building the safe and secure commercial vehicles of tomorrow, please visit: BlackBerry.QNX.com.

About BlackBerry
BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including 175M cars on the road today.  Based in Waterloo, Ontario, the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety and data privacy solutions, and is a leader in the areas of endpoint security, endpoint management, encryption, and embedded systems.  BlackBerry’s vision is clear – to secure a connected future you can trust.

BlackBerry. Intelligent Security. Everywhere. 

For more information, visit BlackBerry.com and follow @BlackBerry.

Trademarks, including but not limited to BLACKBERRY and EMBLEM Design are the trademarks or registered trademarks of BlackBerry Limited, and the exclusive rights to such trademarks are expressly reserved. All other trademarks are the property of their respective owners. BlackBerry is not responsible for any third-party products or services.

Media Contact:
BlackBerry Media Relations
+1 (519) 597-7273
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/volvo-group-selects-blackberry-qnx-for-its-dynamic-software-platform-301263992.html

SOURCE BlackBerry Limited

VANCOUVER, BC, April 7, 2021 /PRNewswire/ – CRH Medical Corporation (TSX: CRH) (NYSE American: CRHM) (“CRH” or the “Company“) announced today that it has filed with the U.S. Securities and Exchange Commission (the “SEC“) a Current Report on Form 8-K containing certain disclosures that are intended to amend and supplement the Company’s proxy statement and management information circular, dated March 19, 2021 (the “Circular“), relating to the special meeting of CRH securityholders that will be held in connection with the proposed acquisition of CRH by WELL Health Technologies Corp. (the “Arrangement“), which Circular was previously mailed to securityholders. The Current Report and supplemental disclosures are available on the SEC’s website at http://www.sec.gov, on SEDAR at www.sedar.com and on the Company’s website at http://investors.crhsystem.com.

The supplemental disclosures were prepared in response to certain complaints filed against CRH and the members of the CRH Board of Directors by purported individual CRH shareholders in the U.S., which complaints allege that the Circular was materially incomplete and misleading, in violation of certain U.S. securities laws. The defendants believe that all of the complaints are without merit and that no further disclosure is required to supplement the Circular under applicable laws. However, in order to moot the plaintiffs’ unmeritorious disclosure claims, to avoid the risk that the foregoing actions may delay or otherwise adversely affect the consummation of the Arrangement and to minimize the expense of defending such actions, CRH voluntarily made the disclosures set forth in the Current Report to supplement the disclosures contained in the Circular. The supplemental disclosures should be read in conjunction with the disclosures contained in the Circular, which should be carefully read in its entirety. The Circular is available on the SEC’s website at http://www.sec.gov, on SEDAR at www.sedar.com and on the Company’s website at http://investors.crhsystem.com.

The filing will not affect the consideration to be received by CRH shareholders in connection with the Arrangement, or the timing of the special meeting of the Company’s securityholders scheduled for April 16, 2021, at 9:00 a.m., Vancouver time, which is being held in a virtual format conducted via live audio webcast at https://web.lumiagm.com/281719465. At the meeting, CRH securityholders will be asked to vote on a special resolution to approve the Arrangement (the “Arrangement Resolution“), and CRH shareholders will be asked to vote on a proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to CRH’s named executive officers in connection with the Arrangement (the “Compensation Proposal“). The CRH Board of Directors continues to unanimously recommend that CRH securityholders vote FOR the approval of the Arrangement Resolution and that CRH shareholders vote FOR the Compensation Proposal.

Cautionary Note Regarding Forward-Looking Statements

Certain statements and information included or incorporated by reference in this document may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements“). Forward looking statements include statements regarding the acquisition of the Company by WELL, as well as all other statements that are not statements of historical fact. Forward-looking statements are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “plan,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements reflect current expectations of management regarding future events and performance as of the date of this document and involve known and unknown risks, uncertainties and other factors which may cause our actual results to be materially different those expressed or implied by any forward-looking statements. These forward-looking statements should not be read as guarantees of future results, and there can be no assurance that the results expressed or implied by any forward-looking statements will be achieved. Important factors that could cause actual results to differ materially from the results discussed in forward-looking statements include: (i) the risk that the Company’s securityholders do not approve the proposed transaction; (ii) the risk that regulatory or other approvals required for the transaction may be delayed or not obtained, or are obtained subject to conditions that are not anticipated; (iii) the possibility that certain other conditions to the consummation of the proposed transaction will not be satisfied or completed on a timely basis, or at all; (iv) the risk that the financing necessary for the consummation of the proposed transaction is unavailable at the closing; (v) the risk of disruption from the announcement, pendency and/or completion of the potential transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; (vi) uncertainties related to developments in the COVID-19 pandemic and its impact on the Company’s operations and the completion of the proposed transaction; and (vii) uncertainties related to general economic, financial, regulatory and political conditions, as well as potential changes in law and regulatory interpretations.

Additional factors that could cause actual results to differ materially from expectations include, without limitation, the risks identified by the Company in its most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K, which are available on EDGAR at www.sec.gov/edgar.shtml or on the Company’s website at www.crhmedcorp.com. The Company disclaims any intent or obligations to update or revise publicly any forward-looking statements whether as a result of new information, estimates or options, future events or results or otherwise, unless required to do so by law.

View original content:http://www.prnewswire.com/news-releases/crh-medical-corporation-updates-special-meeting-materials-in-connection-with-proposed-arrangement-with-well-health-technologies-corp-301263975.html

SOURCE CRH Medical Corporation

EMERYVILLE, Calif., April 7, 2021 /PRNewswire/ — Amyris, Inc., (Nasdaq: AMRS) a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced a 5-year partnership with Reese Witherspoon as global brand ambassador for Biossance^®, one of the fastest growing clean and sustainable skincare brands in the world.

Together, Reese and Biossance will partner to shape the future of clean beauty, leveraging her global leadership in the entertainment industry, and passion for education, with Biossance’s unparalleled expertise in skincare efficacy, and clean beauty science. 

Reese, the Biossance brand team and its industry-leading scientists will create content that is engaging and educational, empowering today’s beauty community to become savvier, more health-conscious consumers. She will also develop curated and limited-edition items featuring her favorite Biossance products.

“I have always been conscious of what’s being put on my skin, but after all the time I’ve spent on-sets throughout my career, I’ve learned so much,” Reese Witherspoon explains. “As my knowledge has grown so has my desire to use clean and consciously created products. I not only fell in love with Biossance’s products, especially their Rose Oil, but also their innovative, female-led team and their mission towards a sustainable future. My skin has never felt healthier and I’m proud to work with such a strong industry leader in sustainability and care for our planet.”

“Reese is a champion of empowerment and education. Her relatability, genuine desire to learn and passion for her beliefs engages everyone she reaches,” said Biossance President Catherine Gore. “We are honored to partner with her in advancing our mission toward a more sustainable future for our planet through clean beauty. Biossance continues to experience industry-leading growth and we expect our partnership with Reese to expand our global consumer awareness while continuing to improve the effectiveness of our mission forward, science-led clean beauty strategy.”

About Biossance
As pioneers in clean beauty, we use our expertise to create groundbreaking, high-performance skincare powered by squalane. We do more than just make clinically proven, award-winning products. We are shaping the future of clean beauty by reinventing ingredients, creating more sustainable processes, and empowering a community of changemakers. We believe science and beauty should co-exist, with no compromise, and that consumers should never be asked to choose between the most effective products and consciously created, sustainable formulas.

About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 3,000 products from the world’s top brands, reaching more than 200 million consumers. Amyris is proud to own three consumer brands – all built around its No Compromise® promise of clean ingredients: Biossance® clean beauty skincare, Pipette® clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane. For more information, please visit www.amyris.com.

Amyris, the Amyris logo, No Compromise, Biossance, Pipette, and Purecane are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding Amyris’s expectation of extending consumer reach and awareness, leveraging marketing investments and continuing industry leading growth in clean beauty and its plan to shape the future of clean beauty through its partnership with Reese Witherspoon. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to realizing the expected benefits of the partnership with Reese Witherspoon; potential delays or failures in development, production, and commercialization of new molecules and products; risks related to Amyris’s reliance on third parties; risks related to Amyris’s liquidity and ability to fund operating and capital expenses; and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amyris-brand-biossance-partners-with-reese-witherspoon-to-accelerate-clean-beauty-movement-301264014.html

SOURCE Amyris, Inc.

CHICAGO, April 7, 2021 /PRNewswire/ — Opportunity Financial, LLC (“OppFi“), a leading financial technology platform that powers banks to help the everyday consumer gain access to credit, announced today it is working with Mastercard, First Electronic Bank and Deserve to launch OppFi Card, a new mobile-first credit card designed to expand credit to millions of consumers who are locked out of mainstream financial products. OppFi Card will be powered by First Electronic Bank and Deserve and will feature Mastercard as the exclusive card network.

“OppFi’s mission is to expand financial access to millions of everyday consumers who are locked out of traditional financial products, of which about 60 million U.S. adults lack access to credit of choice. OppFi Card is the next product phase to fulfill this need,” said Jared Kaplan, chief executive officer, OppFi. “OppFi Card can bridge the gap and help graduate consumers closer to mainstream credit options with simple, revolving credit that can improve their financial health.”

OppFi Card will be issued by First Electronic Bank, Member FDIC, and will serve to help graduate current OppFi customers to mainstream credit options. Upon approval, cardholders will be instantly able to access their OppFi Card by directly adding it to their mobile wallets from the OppFi mobile app. This will allow cardholders to access their card information almost immediately to begin making purchases online, in-app, and at the point of sale. Cardholders can also receive a physical card that supports all payment types, including EMV chip and contactless payments.

“We look forward to working closely with OppFi to deliver best-in-class payments experiences to cardholders looking for meaningful solutions to build their access to the digital economy,” said Sherri Haymond, executive vice president, Digital Partnerships at Mastercard.

“Through our partnership with OppFi, First Electronic Bank is committed to building innovative and dynamic financial products for underserved and emerging communities. OppFi Card is the critical next step in this mission to expand new credit products and build expanded financial access for customers,” said Derek Higginbotham, chief executive officer and president, First Electronic Bank.

“There is complete mission-alignment between Deserve and OppFi Card. Together, we are able to provide the mobile-first technology that is designed to expand credit access and create a better and more streamlined experience for the customer,” said Kalpesh Kapadia, chief executive officer and co-founder, Deserve.

OppFi plans to launch OppFi Card in the second half of 2021. To learn more or to sign up for the launch waitlist, please visit www.oppficard.com.

Earlier this year, OppFi and FG New America Acquisition Corp. (NYSE: FGNA), a special purpose acquisition corporation, entered into a definitive agreement for a business combination that would result in OppFi becoming a public company.

About OppFi

OppFi is a leading financial technology platform that powers banks to offer accessible products and a top-rated experience to everyday consumers. Through its unwavering commitment to customer service, OppFi helps consumers who are turned away by traditional providers build a better financial path. To date, OppFi has facilitated the issuance of more than 1.5 million loans. The company is an Inc. 5000 company for five straight years, a Deloitte’s Technology Fast 500™, and the eighth fastest-growing Chicagoland company by Crain’s Chicago Business. The company was also named on Forbes America 2021 list of America’s Best Startup Employers and Built In’s 2021 Best Places to Work in Chicago. OppFi maintains an A+ rating from the Better Business Bureau (BBB) and maintains a 4.9/5 star rating with more than 14,000 online customer reviews, making it one of the top customer-rated financial platforms online. For more information, please visit oppfi.com.

About First Electronic Bank

First Electronic Bank is an FDIC-insured, state-chartered industrial bank headquartered in Salt Lake City, Utah, Member FDIC. First Electronic Bank believes in building a financial services industry that is inclusive and effective for the diverse range of consumers, businesses, and partners that rely on it. Learn more at www.firstelectronicbank.com.

About Deserve

Through a digital-first, mobile-centric, highly configurable credit card solution, Deserve is powering the future of fintech. Using machine learning and alternative data, Deserve partners with universities, associations, financial institutions, fintechs, and modern consumer brands to develop, rapidly deploy and power white label and co-branded credit card programs for any audience. Deserve is a venture-backed fintech company whose investors include Goldman Sachs, Sallie Mae, Accel, Pelion Venture Partners, Aspect Ventures, and Mission Holdings. For more information, please visit  http://www.deserve.com.

About FGNA

FG New America Acquisition Corp., (NYSE: FGNA), is a NYSE-listed blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. For more information, please visit www.fgnewamerica.com.

Media Inquiries:

[email protected]

Forward-Looking Statements

This information includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. FGNA’s and OppFi’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, OppFi’s expectations with respect to the future performance of OppFi’s platform, OppFi’s expectations for its growth and profitability, OppFi’s new products and their performance and OppFi’s beliefs regarding the impact of the proposed business combination on its business. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside FGNA’s and OppFi’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive business combination agreement (the “Agreement”); (2) the outcome of any legal proceedings that may be instituted against FGNA and OppFi following the announcement of the Agreement and the transactions contemplated therein; (3) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of FGNA, certain regulatory approvals or satisfy other conditions to closing in the Agreement, including with respect to the levels of FGNA stockholder redemptions; (4) the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement or could otherwise cause the transaction to fail to close; (5) the impact of COVID-19 on OppFi’s business and/or the ability of the parties to complete the proposed business combination; (6) the inability to obtain or maintain the listing of the combined company’s shares of common stock on the New York Stock Exchange following the proposed business combination; (7) the risk that the proposed business combination disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination; (8) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of OppFi to grow and manage growth profitably and retain its key employees; (9) costs related to the proposed business combination; (10) changes in applicable laws or regulations; (11) the possibility that OppFi or FGNA may be adversely affected by other economic, business, and/or competitive factors; (12) whether OppFi will be successful in launching OppFi Card, including whether there will be consumer or market acceptance of OppFi Card; and (13) other risks and uncertainties indicated from time to time in FGNA’s proxy statement relating to the proposed business combination, including those under “Risk Factors” therein, and in FGNA’s other filings with the SEC. FGNA and OppFi caution that the foregoing list of factors is not exclusive. FGNA and OppFi caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. FGNA and OppFi do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Important Information and Where to Find It

In connection with the proposed business combination, FGNA has filed a preliminary proxy statement with the SEC and intends to file a definitive proxy statement with the SEC. FGNA’s stockholders and other interested persons are advised to read the preliminary proxy statement and the amendments thereto and, when available, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed business combination, as these materials will contain important information about OppFi, FGNA and the proposed business combination. When available, the definitive proxy statement and other relevant materials for the proposed business combination will be mailed to stockholders of FGNA as of a record date to be established for voting on the proposed business combination. Stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s web site at www.sec.gov, or by directing a request to: FG New America Acquisition Corp., Attention: Hassan Baqar, Chief Financial Officer, 105 S. Maple Street, Itasca, Illinois 60143.

Participants in the Solicitation

FGNA and its directors and executive officers may be deemed participants in the solicitation of proxies from FGNA’s stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in FGNA was filed in the preliminary proxy statement for the proposed business combination and is available at www.sec.gov. Additional information regarding the interests of such participants will be contained in the definitive proxy statement for the proposed business combination when available.

OppFi and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of FGNA in connection with the business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination was included in the preliminary proxy statement for the proposed business combination. Additional information regarding the interests of such participants will be contained in the definitive proxy statement for the proposed business combination when available.

Non-Solicitation

This information shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination. This information shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

View original content to download multimedia:http://www.prnewswire.com/news-releases/oppfi-teams-up-with-mastercard-first-electronic-bank-and-deserve-to-introduce-oppfi-card-301263758.html

SOURCE OppFi

CALGARY, AB, April 7, 2021 /PRNewswire/ – Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), is pleased to announce the appointment of Ian McKinnon to its board of directors, effective immediately. Mr. McKinnon joins Barry Foster, Lester Fernandes, Taylor Gray, and Craig O’Neill as an independent board member.

Mr. McKinnon has been a director of numerous public and private technology companies since 2002, including 12 years on the board of Constellation Software Inc. Among other roles, he currently serves as board chair of MessagePoint, a privately owned technology company. Prior to 2007, he was President and Chief Executive Officer of TSX/Nasdaq-listed Certicom Corp (2002 to 2007) and TSX-listed Promis Systems Corporation (1995 to 2000). From 1981 to 1994 he held various sales and senior management positions at Digital Equipment Corporation in Canada and, ultimately, Singapore where he served as Managing Director. Mr. McKinnon is a graduate of McMaster University and attended the INSEAD Business School Advanced Management Program. 

Barry Foster, Sylogist’s Chairman, commented: “We are very pleased to welcome Ian McKinnon to our board. He brings a wealth of technology market knowledge, as well as vast experience growing companies both organically and via M&A. Ian’s insights and his independence will be valuable as Sylogist refines and executes on its accelerated growth strategy.”

About Sylogist

Sylogist is a software company that, through strategic acquisitions, investments and operations management, provides comprehensive, mission-critical ERP and CRM solutions, including fund accounting, case management, grant management and payroll, to public service organizations. Sylogist’s customers include all levels of government, nonprofit organizations, non-governmental organizations and educational institutions, as well as public compliance driven and funded companies. The Company delivers highly scalable, multi-language, multi-currency software solutions, which serve the needs of an international clientele.

Full financial statements together with Management’s Discussion and Analysis are available on SEDAR at www.sedar.com.

The Company’s stock is traded on the Toronto Stock Exchange under the symbol SYZ. Information about Sylogist can be found at www.sylogist.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/sylogist-announces-board-appointment-301263640.html

SOURCE Sylogist Ltd.

• IRD teams up with the National Research Council and University of Manitoba to create a uniquely Canadian transportation data vault
• Road and weather data, analytics and Artificial Intelligence to be used to enhance decision-making on infrastructure development and emergency response

SASKATOON, SK, April 7, 2021 /PRNewswire/ – International Road Dynamics Inc. (“IRD” or the “Company”), a Quarterhill Inc. (“Quarterhill”) company (TSX: QTRH) (OTCQX: QTRHF) announced today that it will be participating in a research project with the University of Manitoba (“UM”) and the National Research Council (“NRC”) on improvements to highway transportation infrastructure, reliability and safety in the Canadian Prairie and Northern Region. The NRC is the principal funder of the project.

Canada’s vast prairie and northern region relies on roads that must be kept fluid, resilient, and safe for freight transport. In 2017, trucking accounted for 55% of total merchandise exports by value in the region. Major industries in the region—including agriculture, petroleum, forestry, and mining—could not function without a reliable and safe road freight transport system. This network is sparse and subject to seasonal changes, making it prone to risks and hazards that can disrupt the overall supply chain. With limited public sector dollars available for road development, governments are turning to tech-enabled solutions to help make better informed investment, maintenance and response decisions related to their infrastructure.

Together, IRD, UM and NRC seek to address this challenge. IRD and UM are developing a leading-edge mobile traffic and weather monitoring system that will be deployed throughout the region to capture data over a period of five years. The first of its kind in Canada, these systems will be situated at Weigh-in-Motion and truck traffic monitoring sites throughout Manitoba. The aggregated data will form the basis of a transportation data vault that will enable multiple data-intensive investigations in the future.

Researchers at the NRC will use Artificial Intelligence (“AI”) to run scenario analysis on the data vault to assess the impact on highway networks from various types of risks and hazards, such as flooding, extreme weather, hazardous materials incidents and longer-term impacts related to climate change. Results from this analysis will better equip decision-makers to respond to one-time incidents as well as planning for more sweeping long-term environmental changes in order to preserve the resilience and reliability of the highway network.

Rish Malhotra, IRD President & CEO, commented, “We are pleased to partner with UM and the NRC to advance these technologies and methods for mobile traffic data collection and analysis. Our work on this project will generate high-quality data that will inform far-reaching improvements to traffic planning, which will have a significant impact on how the transportation industry affects the economy and the people and communities it is meant to serve. The findings from this project stand to benefit transportation planning and technology well beyond the Canadian prairies, creating potential new business opportunities for IRD both domestically and internationally.”

About IRD
IRD is a dynamic technology company engaged in developing key components and advanced systems for the next generation of transportation networks. Together with subsidiaries Sensor Line, PAT Traffic and ICOMS Detections, IRD supplies Intelligent Transportation Systems (ITS) to private corporations, transportation agencies, and highway authorities around the world. IRD’s systems make highways safer, greener, and more efficient. Known globally as a trusted partner providing sales, service, and installation support on major ITS projects for over 40 years, IRD contributes to creating smarter cities by empowering engineering and urban planning professionals to access reliable traffic data. For more information: www.irdinc.com

About Quarterhill
Quarterhill is a growth-oriented company in the Intellectual Property and Intelligent Transportation System (ITS) industries. Our goal is to pursue an investment strategy that capitalizes on attractive market trends in both ITS and its adjacent markets. Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF. For more information: www.quarterhill.com

Forward-Looking Information
This news release contains forward-looking statements regarding IRD, Quarterhill and their businesses. Forward-looking statements are based on estimates and assumptions made by IRD and/or Quarterhill in light of their experience and perception of historical trends, current conditions, expected future developments and the expected effects of new business strategies, as well as other factors that IRD and/or Quarterhill believe are appropriate in the circumstances. The forward-looking events and circumstances discussed herein may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting IRD and/or Quarterhill, including: potential risks and uncertainties relating to the ultimate geographic spread of the novel coronavirus (“COVID-19”); the severity of the disease; the duration of the COVID-19 outbreak; actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact; the potential negative impacts of COVID-19 on the global economy and financial markets and any resulting impact on IRD and/or Quarterhill and/or their businesses. Other factors include, without limitation, the risks described in Quarterhill’s February 27, 2020 annual information form for the year ended December 31, 2019 (the “AIF”). Copies of the AIF may be obtained at www.sedar.com. IRD and Quarterhill recommend that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of IRD’s forward-looking statements. IRD has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content:http://www.prnewswire.com/news-releases/ird-joins-project-to-enhance-the-reliability-and-development-of-canadas-prairie-and-northern-region-transportation-network-301263913.html

SOURCE International Road Dynamics